ArticleBMC gastroenterology2025
Prognostic value of preoperative serum tumor markers in gallbladder cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate the clinical factors related to poor prognosis of gallbladder cancer (GBC) patients, and to develop a prognostic model which may provide the guidance for clinical decision-making.
methodsThe clinical and pathological data of 136 patients with GBC admitted and treated in the Hunan Provincial People's Hospital from January 2018 to July 2023 were retrospectively analyzed. All patients were followed up periodically by telephone, with the final follow-up on July 15, 2024. The Kaplan-Meier method was employed for univariate survival analysis. The log-rank test was utilized to assess differences in survival curves. A Cox regression model was applied for multivariate analysis to identify independent prognostic factors for GBC. Independent prognostic factors identified through Cox modeling were integrated into a nomogram. Finally, receiver operating characteristic (ROC) curves and calibration curves were plotted for 1-, 2-, and 3-year survival predictions.
resultsGBC patients were predominantly female and elderly. GBC patients with diabetes, jaundice and Child-Pugh B/C classification of liver function had poorer overall survival (OS) outcomes. Elevated serum tumor biomarkers CA19-9, CA125, CEA, CA724 and CYFRA21-1 were associated with unfavorable OS in GBC patients. Additionally, the differentiation grade, Lymphovascular invasion (LVI), perineural invasion (PNI), clinical staging and TNM staging were also related to the OS of GBC patients. For GBC patients who underwent surgical treatment, OS was significantly improved, with the most notable improvement observed in those who received radical surgery. GBC patients treated with chemotherapy-based drug treatment experienced an improvement in OS. Multivariate Cox regression analysis revealed that diabetes, elevated CA125, and advanced TNM stage were independent risk factors for GBC prognosis, while chemo-immunotherapy/targeted therapy was an independent protective factor.
conclusionDiabetes, elevated CA125 levels, TNM stage, and chemo-immunotherapy/targeted therapy are independent prognostic factors for GBC patients, which could be used to develop a nomogram model and contribute to provide the guidance for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.